This piece breaks down what "brightening" treatments clinically address, what the regulatory landscape actually requires, and what the evidence supports for each option.
In clinical practice, almost no patient walks in asking to treat melasma by name. Most describe dark patches, uneven tone, or a complexion that looks tired. Consequently, the first task in any consultation is translating that description into an actual diagnosis.
Melasma shows up as symmetrical brown patches, usually across the cheeks and forehead, and is strongly linked to hormonal shifts from pregnancy, contraceptives, or thyroid conditions. It responds to treatment, but it also relapses easily, particularly with sun exposure. This makes it one of the more frustrating conditions to manage long-term, for patient and clinician alike.
This is the dark mark left behind after acne, an injury, or even an aggressive facial. It is not a pigment disorder on its own; it is the skin's healing response overproducing melanin. However, it usually fades faster than melasma with the right topical regimen.
Years of unprotected sun exposure show up as flat brown patches, typically across the cheekbones and forehead. Consequently, sunscreen is not a footnote in any brightening treatment plan. It is the precondition for the other steps to work at all.
Hydroquinone was the standard lightening ingredient in over-the-counter creams in India until 2019. That year, CDSCO moved it under Schedule H of the Drugs and Cosmetics Rules, meaning it can no longer be sold without a doctor's prescription. The change followed documented cases of ochronosis, a condition where hydroquinone paradoxically darkens and thickens the skin with prolonged, unsupervised use.
Mercury-based skin lightening products remain a global public health concern, and the World Health Organization has flagged them as a source of serious kidney and neurological damage. The US FDA's own updated consumer guidance still warns against over-the-counter products containing mercury or unapproved hydroquinone. For a clinic or patient, the practical takeaway is the same: any product promising fast whitening results without a prescription or clinical supervision is worth being suspicious of.
As this publication has covered, India's dermatology segment has grown quickly since the pandemic. Regulatory clarity around pigmentation treatments has had to catch up to that growth rather than lead it.
Beyond hydroquinone, dermatologists commonly prescribe azelaic acid, tranexamic acid, and combination formulations for pigmentation. These require an accurate diagnosis first, since treating melasma and post-inflammatory pigmentation with the same cream rarely works well.
Chemical peels, Q-switched, and PICO laser toning all work through controlled removal or breakdown of excess pigment. They are effective for sun-induced pigmentation and some forms of melasma, though melasma in particular can rebound if triggered by sun exposure or hormonal changes. Neither is a one-time fix; both need maintenance sessions to hold results.
Glutathione, taken orally or by injection, remains one of the most requested brightening treatments we see in the clinic. It is not currently an FDA-approved indication for skin lightening, and the quality of large-scale trial evidence behind it is thinner than most patients assume. In practice, we present it as one option among several rather than a guaranteed result, and we are candid with patients about where the evidence is still developing.
A treatment plan that starts with a diagnosis, not a product name, is the clearest sign of a properly run practice. This holds as much for Bangalore's aesthetic market as anywhere else in India, where the best skin care clinic in Bangalore is typically the one asking more questions before recommending anything. We have laid out our own clinical approach to these treatments in more detail here, including how we sequence topical, peel, and laser options across different pigmentation types.
In our own consultations, the pattern is consistent: patients arrive having self-diagnosed as needing "whitening" and leave with a plan built around melasma, post-inflammatory pigmentation, or sun damage instead. That reframing, more than any single product, is usually what determines whether the results actually hold.
Skin Whitening Treatment almost always means treating a specific, diagnosable form of pigmentation, not altering a person's baseline skin tone. The regulatory tightening around hydroquinone and the continued global concern over mercury both point in the same direction: supervised, diagnosis-led treatment outperforms self-directed product use. Whether you're consulting the best skin care clinic in Bangalore or another qualified provider, the quality varies meaningfully by treatment. It is worth asking any clinic to explain the evidence behind its recommendations rather than promising uniform results.
For those of us in this industry: Has patient demand in your own practice shifted from complexion-focused requests toward more specific pigmentation diagnoses, or is that reframing still a work in progress in your market?